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Plants are a significant reservoir of cytotoxic agents, including compounds with the ability to interfere with multidrug-resistant
(MDR) cells. With the aim of finding promising candidates for chemotherapy, 91 native and naturalized plants collected from the
central region of Argentina were screened for their cytotoxic effect toward sensitive andMDRP-glycoprotein (P-gp) overexpressing
human leukemia cells by means of MTT assays. The ethanol extracts obtained from Aldama tucumanensis, Ambrosia elatior,
Baccharis artemisioides, Baccharis coridifolia, Dimerostemma aspilioides, Gaillardia megapotamica, and Vernonanthura nudiflora
presented outstanding antiproliferative activity at 50 𝜇g/mL, with inhibitory values from 93 to 100%, when tested on the acute
lymphoblastic leukemia (ALL) cell line CCRF-CEM and the resistant derivative CEM-ADR5000, while 70–90% inhibition was
observed against the chronic myelogenous leukemia (CML) cell K562 and its corresponding resistant subline, Lucena 1. Subsequent
investigation showed these extracts to possess marked cytotoxicity with IC50 values ranging from 0.37 to 29.44 𝜇g/mL, with most of
them being below 7𝜇g/mL and with ALL cells, including the drug-resistant phenotype, being the most affected. G. megapotamica
extract found to be one of the most effective and bioguided fractionation yielded helenalin (1). The sesquiterpene lactone displayed
IC50 values of 0.63, 0.19, 0.74, and 0.16 𝜇g/mL against K562, CCRF-CEM, Lucena 1, and CEM/ADR5000, respectively. These results
support the potential of these extracts as a source of compounds for treating sensitive and multidrug-resistant leukemia cells and
support compound 1 as a lead for developing effective anticancer agents.
1. Introduction
Leukemia is a malignant disorder with a significant number
of deaths annually [1]. According to GLOBOCAN, about
352,000 new cases of leukemia and 265,000 deaths occurred
worldwide in 2012 [2].
Despite overall improvement in the outcome of conven-
tional leukemia therapies [3, 4], some patients have poor
survival rates [5] or suffer from side effects of the drugs
administered [3, 4, 6], and relapse is often observed [7]. In
addition, a major problem in the treatment of leukemia is the
development of resistance to chemotherapeutic agents. Many
cancers, including leukemia, are resistant to a wide array of
chemically and functionally unrelated agents, a phenomenon
known as multidrug resistance (MDR).
Various mechanisms underlie this type of resistance, the
most common being overexpression of the P-glycoprotein (P-
gp) transporter (ABCB1/MDR1) [8]. This protein, located in
the cell membranes, is involved in the traffic of chemothera-
peutic drugs outside the cancer cell [6] or in the sequestration
of these in cytoplasmic organelles, preventing their therapeu-
tic effect [9]. More than a third of cells from patients with
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leukemia were positive to P-gp [10]. High levels of this pump
were detected in about 50% of patients with chronic myel-
ogenous leukemia (CML)unresponsive to chemotherapy [11],
while 12 and 29% of patients with acute myeloid leukemia
(AML) showed high and intermediate P-gp expression, re-
spectively [12]. For these reasons, academy and industry still
concentrate on finding promising candidates for an effective
and safe therapy for leukemia.
A considerable number of plants have been recognized
with rich potential as a therapeutic resource, and many of
their derivedmolecules were active on leukemia cells, includ-
ing resistant phenotypes [6]. Many compounds with medici-
nal properties have been obtained from flora from Argentina
[8, 13–16], but this resource is far from being completely ex-
plored.
The present work reports antiproliferative activity on sen-
sitive and P-gp overexpressing leukemia cell lines of a panel
of 91 extracts obtained from native and naturalized plants of
Central Argentina. One of the most potent extracts, Gaillar-
dia megapotamica, was submitted to bioguided fractionation
to further isolate the active principle responsible for its
cytotoxicity.
2. Materials and Methods
2.1. Plant Material and Extract Preparation. Plants were
collected in the hills of Co´rdoba Province, Argentina, from
November toMarch 2016-2017. Voucher specimens have been
deposited in the “Marcelino Sayago”Herbariumof the School
of Agricultural Science, Catholic University of Co´rdoba, and
were authenticated by the botanist, G. Ruiz. Plants were
selected according to their availability, accessibility, and espe-
cially the lack of scientific information about their activity
and/or chemical pattern. Crushed, air-dried material (200 g)
was extracted by 48 h maceration with 700mL of 96%
ethanol. The yields of each active extract, obtained after ex-
haustive solvent removal and expressed as percentage weight
of air-dried crushed plant material, are shown in Table 2.The
phytochemical profiles of the active extracts were obtained by
HPLC (see supplementary material (available here)). Extract
solutions were prepared immediately prior to testing.
2.2. Chemicals, Equipment, and Reagents. 3-(4,5-Dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
and lectin from Phaseolus vulgaris (PHA) were purchased
from Sigma Aldrich, (Sigma-Aldrich Co., St Louis, MO).
Doxorubicin hydrochloride (DOX, 99.8%, Synbias Pharma
Ltd.) was obtained from Nanox Release Technology (Buenos
Aires, Argentina) and was used dissolved in bidistilled water.
RPMI-1640 and cell culture reagents Gibco were purchased
from Invitrogen Life Technologies (Carlsbad, CA). Sterile
plastic material was purchased fromGreiner Bio-One (Frick-
enhausen, Germany). All solvents were HPLC grade. 1H- and
13C-NMR and two-dimensional spectra were recorded with a
Bruker AVANCE II 400 spectrometer (Bruker Corporation,
Ettlingen, Germany) with tetramethylsilane (TMS) as the
internal reference. HPLC was performed on a Shimadzu
LC-10 AS (Shimadzu Corp., Tokyo, Japan), equipped with a
Luna C18, 250 × 4.6mm reversed-phase column.The mobile
O
O
OH
O
Figure 1: Chemical structure of helenalin (1).
phases were ACN/H2O 30 : 70, ACN/H2O 10 : 90, and ACN/
H2O 70 : 30 with UV detection at 210 and 280 nm.
2.3. Bioguided Isolation of the Active Principle from Gaillardia
megapotamica. Thecytotoxic ethanol extract ofG.megapota-
mica (4 g) was initially subjected to vacuum liquid chromato-
graphy on silica gel (622 g, 63–200𝜇m, 11.0 A˚∼24.0 cm;
Macherey & Nagel) eluted with a step gradient of hexane/
diethyl ether (Et2O)/methanol (MeOH) to yield 12 fractions,
which were combined in 8 groups according to their thin
layer chromatography (TLC) profile (F1 to F8). Fractions F1 to
F5 and F7 and F8 were not active at the tested concentration
(10 𝜇g/mL),while fraction F6, elutedwith 100%Et2O,demon-
strated cytotoxic effect at this concentration. Therefore, F6
was further processed by radial preparative chromatography
using an isocratic mobile phase of hexane/Et2O 30 : 70. The
fractions obtained were combined in 10 groups in accordance
with the TLC analysis (F6-1 to F6-10). From fraction F6-6, a
pure compound 1 was obtained by spontaneous crystalliza-
tion (Rt = 9.65, 98.2% purity, by HPLC). This compound, the
remaining F6-6, and the rest of the fractions were further
tested for their cytotoxic activity at 10𝜇g/mL. Only 1 exerted
a toxic effect at this concentration. According to 1H and 13C
NMR spectra (copies of the original spectra are obtainable
from the corresponding author), the compound was iden-
tified as the sesquiterpene lactone helenalin C15H18O4 (1;
𝑚/𝑧 262) [41] (yield 0.79 g/100 g of dried and crushed plant
material, by HPLC) (Figure 1).
2.4. Cell Lines and Culture Conditions. The cytotoxicity of
plant extracts was tested on acute lymphoblastic leukemia
(ALL) CCRF-CEM cells [42] and onCMLK562 cells [43] and
their MDR P-gp overexpressing variants, CEM/ADR5000
and Lucena 1, respectively [8, 44]. Cell lines were routinely
maintained in RPMI-1640 medium supplemented with 10%
heat-inactivated fetal bovine serum (FBS, Natacor, Co´rdoba,
Argentina), 2mM L-glutamine (Invitrogen Life Technolo-
gies, CA, USA), 100 U/mL penicillin (Invitrogen Life Tech-
nologies, CA,USA), and 100 𝜇g/mL streptomycin (Invitrogen
Life Technologies, CA, USA) in a 5% CO2 humidified atmos-
phere at 37∘C.
As previously described, CEM/ADR5000 cells were
exposed once a week to doses of DOX, gradually increasing
from 1.7 to 8.6 𝜇M. The latter concentration was then used
for cell maintenance [44, 45]. Lucena 1 were continuously
cultured in the presence of 60 nM DOX in order to maintain
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P-gp overexpression [8]. Both cell lines were grown in drug-
freemedium 3-4 days before the experiments. Cells were sub-
cultured twice a week and used before the 20th passage. All
experiments were performed with cells in the logarithmic
growth phase, with cell viabilities over 90%, determined by
trypan blue staining.
2.5. Cell Proliferation Assay. To investigate the cytotoxic
potential of the extracts, fractions, and the pure compound,
the MTT colorimetric assay was performed [46]. Briefly, 5 ×
104 cells, suspended in 100𝜇L of growthmedium,were seeded
in 96-well plates containing 100𝜇L ofmedium in the presence
of each tested extract, fraction, or compound previously
dissolved in DMSO (final concentration 1% v/v since no
adverse effects on cell growth were observed at this concen-
tration). The extracts were evaluated at a final concentration
of 50 𝜇g/mL. Following the primary screening, those extracts
with promising activity on all studied cells were tested at
serial dilutions ranging from 50 to 0.012 𝜇g/mL. The isolated
compound was tested at 0.005–10 𝜇g/mL. After 48 or 72 h
for CML or ALL, respectively, 20𝜇L of 5mg/mL solution
of MTT in sterile PBS was added to each well and further
incubated for 4 h. Then, the supernatants were removed and
replaced with 100𝜇L DMSO to solubilize the resulting purple
formazan crystals produced from metabolically viable cells.
Absorbance was measured with an iMark microplate reader
(Bio-Rad, USA) at 595 nm. Twowells were used for each sam-
ple assayed and three independent experiments were per-
formed.
Untreated and DMSO (1%)-treated cells were used as
controls, while DOX (added to reach final concentrations of
0.003 to 40 𝜇g/mL) was used as reference. The percentage of
cytotoxic activity was determined by the following formula:
cytotoxicity (%) = [1 − (optical density of treated cells-optical
density DMSO)/(optical density of control cells-optical den-
sity DMSO)] × 100.
Half-maximal inhibitory concentrations (IC50), the con-
centrations of the tested samples required to inhibit 50%
cell proliferation, were calculated from the mean values of
data from wells. Resistance factors (RF) were calculated by
dividing the IC50 of resistant cells by the IC50 of the corre-
sponding sensitive cell line [47].
2.6. Cytotoxicity on Peripheral Blood Mononuclear Cells
(PBMC). The cytotoxicity of the extracts on peripheral blood
mononuclear cells (PBMC)was evaluated byMTT assay [46].
PBMCwere collected from fresh heparinized blood and sepa-
rated by density gradient centrifugation (Ficoll) as described
by Renno´ et al. [48]. As the current study required samples
from healthy human volunteer donors, ethical approval was
provided by the Catholic University of Co´rdoba Research
Ethics Board. Signed informed consent was obtained from
donors. For the cytotoxicity assay, 1 × 105 PBMC/well was
incubated in duplicate in 96-well plates with PHA 10𝜇g/mL,
in the presence of increasing concentrations of the extracts
(0.05–50 𝜇g/mL) or 1% DMSO for 48 h. Absorbance (Abs)
and percentage of cytotoxicity were determined as described
above and the IC50 values were calculated.
2.7. Statistical Analysis. The results are expressed as mean ±
SE. Data were analyzed with one-way analysis of variance
(ANOVA) and one-tailed unpaired 𝑡 test using GraphPad
Prism software (GraphPad Prism 5.0, GraphPad Software,
Inc., CA,USA), with𝑝 values≤ 0.05 as statistically significant.
IC50s were calculated by GraphPad Prism software, respond-
ing to at least five concentrations of each extract at the 95%
confidence level with upper and lower confidence limits.
3. Results and Discussion
With the aim of finding new agents capable of interfering
with the proliferation of sensitive and MDR leukemia cells,
91 ethanol extracts obtained from different plant species of
Central Argentina were primarily assayed at a fixed con-
centration of 50 𝜇g/mL against a panel of cells consist-
ing of CCRF-CEM and K562 and their respective P-gp
overexpressing counterparts, CEM/ADR5000 and Lucena 1.
The ethanol extracts obtained from Aldama tucumanensis,
Ambrosia elatior, Baccharis artemisioides, Baccharis coridifo-
lia, Dimerostemma aspilioides, Gaillardia megapotamica, and
Vernonanthura nudiflora inhibited proliferation by 93–100%
inALL cell lines while 70–90% inhibitionwas observed in the
CML cells (Table 1). As observed, all the active species belong
to Asteraceae. This could be due to more than a third of
the studied plants being Asteraceae (35%) while the remain-
ing 65% were Amaranthaceae (1%), Apiaceae (1%), Apoc-
ynaceae (1%), Aristolochiaceae (1%), Asclepiadaceae (1%),
Bignoniaceae (4%), Boraginaceae (1%), Capparaceae (1%),
Chenopodiaceae (1%), Dipsacaceae (1%), Euphorbiaceae
(2%), Fabaceae (8%), Lamiaceae (8%), Lomariopsidaceae
(1%), Loranthaceae (1%), Malvaceae (4%), Meliaceae (1%),
Papaveraceae (1%), Poaceae (4%), Polygalaceae (1%), Ranun-
culaceae (1%), Rhamnaceae (1%), Rosaceae (2%), Rutaceae
(1%), Santalaceae (1%), Schizaeaceae (1%), Solanaceae (3%),
Verbenaceae (4%), and Zygophyllaceae (1%). Sesquiterpene
lactones are characteristic compounds among Asteraceae
[49] andmany of these exhibit cytotoxic properties [50, 51]. It
is interesting thatMandevilla pentlandiana andMicroliabum
candidum displayed a complete inhibitory effect on the
proliferation of both ALL cell lines with moderate activity on
CML cell lines (Table 1). Bibliographic information about the
traditional uses, biological activity, and chemical constituents
of the most active plants is listed in Table 2.
These active extracts were further assessed for their IC50
values in order to determine their level of effectiveness. As
observed in Table 3, IC50 ranged from 0.37 to 29.44 𝜇g/mL.
All extracts, except A. tucumanensis and A. elatior against
CML cell lines, showed a strong cytotoxic effect with IC50
values lower than 20𝜇g/mL. This value is the threshold
established by theNational Cancer Institute (USA,NCI) plant
screening program for an extract to be considered active fol-
lowing an incubation period of 48 and 72 h [52]. As observed,
most of them showed IC50 values lower than 7 𝜇g/mL. The
G. megapotamica and D. aspilioides extracts were the most
effective among those with less toxic effect on PBMC.
The A. elatior extract was highly specific, since it showed
outstanding proliferation-inhibiting properties against ALL
cells but not against CML cells (𝑝 < 0.05). The extract ob-
tained from D. aspilioides, although active against all the
cell lines, also induced specific cytotoxic activity, being more
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Table 3: Half-maximal inhibitory concentrations of most effective extracts.
Species IC50 (𝜇g/mL) (mean ± SE)
CCRF-CEM CEM/ADR5000 RF K562 Lucena 1 RF PBMC
Aldama tucumanensis 5.39 ± 0.23a,∗∗∗ 17.56 ± 0.50a,b,∗∗∗ 3.26 20.24 ± 1.26a,b,∗∗∗ 29.44 ± 5.82b,† 1.45 9.13 ± 1.84
Ambrosia elatior 5.84 ± 1.07a,∗∗ 2.73 ± 0.63a,∗∗∗ 0.47 19.16 ± 2.48b,∗∗,† 21.93 ± 2.91b,†† 1.14 4.01 ± 0.67
Baccharis artemisioides 1.15 ± 0.10a,∗∗∗ 0.94 ± 0.24a,∗∗∗ 0.82 1.90 ± 0.33a,∗ 5.74 ± 0.14b,∗∗∗,††† 3.02 0.95 ± 0.21
Baccharis coridifolia 0.37 ± 0.03a,∗∗∗ 5.89 ± 0.87b,∗∗∗,††† 15.92 0.51 ± 0.07a 1.08 ± 0.11a,∗∗∗ 2.12 0.08 ± 0.01
Dimerostemma aspilioides 1.60 ± 0.07a,∗∗∗ 1.18 ± 0.30a,∗∗∗ 0.74 6.89 ± 0.50b,∗∗∗,† 10.38 ± 1.16b,∗∗,†† 1.51 2.69 ± 0.53
Gaillardia megapotamica 0.70 ± 0.03a,∗∗∗ 1.21 ± 0.005b,∗∗∗ 1.73 2.77 ± 0.02c,∗∗∗ 5.95 ± 0.17d,∗∗∗,† 2.15 2.76 ± 0.52
Vernonanthura nudiflora 2.21 ± 0.08a,∗∗∗,†† 6.38 ± 0.20b,∗∗∗,† 2.89 6.41 ± 0.91b,∗∗,† 10.76 ± 0.78c,∗∗ 1.68 13.70 ± 1.06
doxorubicin 0.07 ± 0.0006a >40††† >571 0.78 ± 0.14a 22.99 ± 1.18b,††† 29.47 0.39 ± 0.02
Results represent the mean ± SE. Means followed by the same letter in each row were not significantly different (Tukey, 푝 > 0.05). Statistical comparisons
between extracts and doxorubicin were analyzed by one-tailed unpaired 푡 test. ∗ ∗ ∗ indicates 푝 < 0.001, ∗∗ indicates 푝 < 0.01, and ∗ indicates 푝 < 0.05.
Statistical comparisons between leukemia cells with respect to PBMC were analyzed by ANOVA-Tukey’s multiple comparison test. ††† indicates 푝 < 0.001,
†† indicates 푝 < 0.01, and † indicates 푝 < 0.05.
effective on ALL cell lines than on CML cells (𝑝 < 0.05). B.
artemisioides and B. coridifolia extracts were highly potent,
being equally active (𝑝 > 0.05) against almost all the assayed
cell lines, with IC50 values from 0.37 to 5.89 𝜇g/mL, and at
the same time were themost toxic against PBMC.Most of the
extracts showed significantly different cytotoxic effects (𝑝 <
0.001–0.05) with respect to DOX, with the same or lower
activity in the case of CCRF-CEM and K562, but the same
or greater effectiveness in the resistant cells, CEM/ADR5000
and Lucena 1. The latter were >570-fold and 29-fold more
resistant to DOX than their parental cell lines, CCRF-CEM
and K562, respectively (Table 3).
It is remarkable that extracts from A. elatior and D.
aspilioides displayed collateral sensitivity (CS) with CEM/
ADR5000 compared to the parental cell line CCRF-CEM
(degree of resistance 0.47 and 0.74, resp.) and lack of cross-
resistance regarding Lucena 1. Except B. coridifolia, to which
both P-gp overexpressing cells showed cross-resistance, the
rest of the extracts showed this phenomenon only in one
resistant cell. This classification is taken into consideration
followingHall et al., [53] who defined RF values ≥ 2 as signifi-
cant cross-resistance toward a compound, while values lower
than 1 indicate a CS agent.
As mentioned, G. megapotamica was identified as one of
the most active species. After submitting this plant to biogu-
ided isolation, helenalin (1) was obtained. This sesquiterpene
lactone showed outstanding IC50 values against K562 cells
and their MDR counterpart Lucena 1 of 0.63 ± 0.06 and
0.74±0.06 𝜇g/mL, respectively (2.53±0.05 and 2.83±0.24 𝜇M,
resp.) while 0.19 ± 0.01 and 0.16 ± 0.01 𝜇g/mL were obtained
against CCRF-CEM and its respective drug-resistant pheno-
type CEM/ADR5000 (0.74 ± 0.05 and 0.59 ± 0.05 𝜇M, resp.).
In coincidence with the results obtained for the complete
extract, ALL cells were more sensitive to compound 1 than
CML cells.
Although none of these most active species have been
subjected to bioguided isolation to obtain their cytotoxic
principles, there is some related information regarding toxic-
ity on cancer cells of some of their constituents. Leptocarpin,
present in A. tucumanensis, displayed cytotoxic activity
against HT-29, PC-3, DU-145, MDA-MB-231, and MCF7
cells, with IC50 values in the range of 0.72 to 2.32 𝜇g/mL,
by inducing apoptotic death [54]. The values show that this
compound can be considered as active, based on the 4𝜇g/mL
cutoff established by the NCI to identify good cytotoxic com-
pounds [55]. Eupatolide, a germacranolide sesquiterpene lac-
tone also found in this plant, showed potent cytotoxic activity
with an IC50 of 0.47 𝜇g/mL against H.Ep.-2 cell line [56]. The
flavonoid hispidulin, present in A. elatior, has been tested for
cytotoxic activity against Jurkat E6-1, GLC4, and COLO320
cells, showing IC50 ranging from 10.21 to 24.62𝜇g/mL [57,
58]. Other constituents of this plant, dihydroparthenolide
and psilostachyin, were reported as inactive when tested
against KB cells [59]; the same as was found for damsinic
acid tested against U937, Jurkat and Molt 4 [60], while
psilostachyin C showed no effectiveness against HeLa, MCF-
7, or A431 cell lines [61] but was slightly effective against
BW5147 cells, with an IC50 value of 4.89 𝜇g/mL [62]. Chloro-
genic acid showed IC50 values ranging from 1.8–10.7 𝜇g/mL
against HepG2, Hep2, HCT116, RD, and MCF7 [63].
All the Argentinian plants of B. coridifolia and most of
B. artemisioides studied by Rizzo et al. [27] were positive for
the fungal macrocyclic trichothecenes roridins E and H and
verrucarins A and J, which showed strong cytotoxic activity
with IC50 of 0.0018, 0.0055,0.0012 and 0.0022𝜇g/mL, respec-
tively against H4TG cells [64]. When tested against Hep-
2, verrucarin A showed an IC50 value of 0.002 𝜇g/mL [65]
while verrucarins A, J and roridin E were active in the range
from 0.0005 to 0.0042𝜇g/mL against KB and BC1 cells [66].
The compound schottenol glucoside, present in B. coridifolia,
demonstrated a toxic effect against KB cells with an IC50
value of 2.7𝜇g/mL [31].The germacranolide tomenphantinA,
isolated fromD. aspilioides, showedmoderate activity against
KB cells, with an IC50 of 3.0 𝜇g/mL [67].
Some sesquiterpene lactones, among them helenalin and
mexicanin, were obtained from G. megapotamica. Helenalin,
with amean cytotoxic activity of 0.10𝜇g/mL against EN2 cells
[68] induced apoptosis in Jurkat T cells [69] and inhibited
human telomerase activity [70], among other toxic effects in
cancer cells [71]. The activity reported in this work toward
the resistant cell lines makes this compound attractive as
a starting point for obtaining effective cytotoxics against
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multidrug-resistant cells. Mexicanin showed outstanding
toxic effects with an IC50 of 0.14 𝜇g/mL against EN2 cells [68].
Dehydroleucodine exhibited cytotoxicity against a panel of
tumor cells, including eight leukemia cell lines, with IC50
ranging from 1.22 to 4.62 𝜇g/mL [72], and luteolin showed
IC50 of 11.70 and 9.30 𝜇g/mL against GLC4 and COLO320
cells, respectively [57]. V. nudiflora contains many inactive
compounds, such as genkwanin, with an IC50 against KB and
P388 cells of 8.7 and 10𝜇g/mL, respectively [73] and germani-
col, with IC50 29.5 and 35.6 𝜇g/mL against HCT 116 and A549
cell lines, respectively [74], as well as the effective compound
velutin (IC50 = 1.5 𝜇g/mL against KB cells) [73]. In addition,
apigenin showed IC50 values from 7.29 to 16.39 𝜇g/mL against
Jurkat E6-1, GLC4, and COLO320 cell lines [57, 58]. A
mixture of sitosterol and stigmasterol exhibited no cytotoxic
effects against P-388 and HT-29 up to a concentration of
50 𝜇g/mL [75].
4. Conclusions
This study demonstrated that compound 1, isolated from
G. megapotamica, is a promising cytotoxic with outstanding
activity against K562 and CCRF-CEM and their respective
MDR counterparts, Lucena 1 and CEM/ADR5000. This
identifies this sesquiterpene lactone as an important lead for
obtaining therapeutics to act against resistant leukemia cells.
The outstanding antileukemia effect of D. aspilioides and
the scant information about its components and the hyper-
sensitivity of resistant CEM/ADR5000 cells toward its extract
merit further investigation to obtain potential candidates
for improving leukemia chemotherapies, especially against
resistant phenotypes.
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